Loading
A phase 2/3 trial testing Budigalimab in non-small-cell lung cancer, now recruiting.
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT06236438, led by AbbVie, and recruiting on the registry. Official title: A Randomised, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC). Planned enrolment is 840 participants (estimated). The study started in 2024-04-10 and primary completion is expected in 2031-10. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Budigalimab, Livmoniplimab, AbbVie (incl. ImmunoGen, Capstan).
Shares Budigalimab, Livmoniplimab, AbbVie (incl. ImmunoGen, Capstan).
Shares Budigalimab, Livmoniplimab, AbbVie (incl. ImmunoGen, Capstan).
Shares Budigalimab, AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/